Drug name: Lipid Nanocapsules


Related CSCTT Targets

Lipid Nanocapsules [ref.1]

Introduction

The lipid nanocapsules (LNCs) are used as drug molecule carriers for cancer treatment. It have been prepared according to an original method based on a phase-inversion temperature processy. Their structure is a hybrid between polymeric nanocapsules and liposomes because of their oily core which is surrounded by a tensioactive rigid membrane. They have a lipoprotein-like structure. Their size can be adjusted below 100 nm with a narrow distribution. Importantly, these properties confer great stability to the structure (physical stability > 18 months). Blank or drug-loaded LNCs can be prepared, with or without PEG (polyethyleneglycol)ylation that is a key parameter that affects the vascular residence time of the nano-cargos. Other hydrophilic tails can also be grafted. Different anticancer drugs (paclitaxel, docetaxel, etoposide, hydroxytamoxifen, doxorubicin, etc.) have been encapsulated. They all are released according to a sustained pattern. Preclinical studies on cell cultures and animal models of tumors have been performed, showing promising results[1].

Liposomes are composed of vesicular bilayers, lamellae, made of biocompatible and biodegradable lipids such as sphingomyelin, phosphatidylcholine, and glycerophospholipids[2].

[1] Huynh, N. T., et al. (2009). "Lipid nanocapsules: A new platform for nanomedicine." Int J Pharm 379(2): 201-209.
[2] Masserini, M. (2013). "Nanoparticles for brain drug delivery." ISRN biochemistry 2013.

Schema

...

Reference

  • [1] Development and characterization of immuno-nanocarriers targeting the cancer stem cell marker AC133.
    Bourseau-Guilmain, E., et al. (2012). Int J Pharm 423(1): 93-101. [ 21683129 ]

Back to top